<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162821</url>
  </required_header>
  <id_info>
    <org_study_id>GNI-F351-201902</org_study_id>
    <nct_id>NCT04162821</nct_id>
  </id_info>
  <brief_title>Study on Pharmacokinetics of Hydronidone</brief_title>
  <official_title>Clinical Pharmacokinetics of Hydroxynitone Capsules in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Continent Pharmaceutical Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Continent Pharmaceutical Co, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetic characteristics of hydronidone capsules (specification: 30
      mg/ pill) in healthy subjects And the effect of feeding on pharmacokinetics to provide
      evidence for phase II/III clinical trial protocols.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 26, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma drug concentration</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Plasma drug concentration after administration of different doses of hydronidone</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Pharmacokinetics of Hydronidone</condition>
  <arm_group>
    <arm_group_label>60mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>90mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>120mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydronidone</intervention_name>
    <description>Take hydroxynitone capsule</description>
    <arm_group_label>120mg group</arm_group_label>
    <arm_group_label>60mg group</arm_group_label>
    <arm_group_label>90mg group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy volunteers, half male and half female;

          2. Age: from 18 to 45 years old, the age difference of the same group of subjects should
             not be more than 10 years;

          3. Weight: male ≥50kg, female ≥45kg, 19≤BMI≤24 (BMI= weight (kg)/height 2 (m2));

          4. Complete physical examination: vital signs, hematuria routine, blood pregnancy, blood
             glucose, blood lipid,Blood electrolyte, hepatitis b surface antigen, liver and kidney
             function, hepatitis c, HIV and syphilis antibody test, Electrocardiogram, smoke test,
             urine drug screening, alcohol breath test, abdominal ultrasound examination, chest
             X-ray examination No abnormal or abnormal clinical significance;

          5. Detailed understanding of the nature, significance, possible benefits and possible
             disadvantages of the experiment has been obtained before the study I was able to
             communicate well with the researchers, Comply with the requirements of the entire
             study and be able to understand and sign written informed consent.

        Exclusion Criteria:

          1. Have participated in any other clinical trials within the first three months of the
             trial;

          2. Any diseases that may affect the safety of the test or the process of the drug in
             vivo, including But not limited to: heart, liver, kidney, endocrine, digestive tract,
             immune system and respiratory system Those with or existing diseases of the above
             system (especially those with cardiovascular diseases including cardiovascular
             diseases) Any gastrointestinal disease that affects drug absorption (such as irritable
             bowel syndrome symptoms, inflammation) History of sexual bowel), active pathological
             bleeding (such as peptic ulcer), urticaria, epilepsy, past Allergic rhinitis, eczema
             dermatitis, asthma, etc.

          3. (consultation) allergy: if there are two or more drugs, food allergies or lactose
             intolerance Tolerance;

          4. (consultation) any inhibition or induction of liver administration during the first 28
             days of administration of the study drug Drugs for metabolism (common liver enzyme
             inducers: barbiturates Drugs for metabolism (common liver enzyme inducers:
             barbiturates such as phenobarbital, carbamazepine,Aminorumide, griseofulvin,
             aminopropyl, phenytoin, gluconate, rifampicin, desicer Betamethasone. Common liver
             enzyme inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chlorine
             Mycin, isoniazid, sulfonamide, etc. Or had used any medication (pack) within 14 days
             prior to initial administration Including Chinese herbal medicine and health products;

          5. (consultation) have specific food requirements and cannot follow a uniform diet (such
             as standard meals or high fat) Food intolerance) or difficulty swallowing;

          6. (consultation) unable to tolerate venipuncture and/or having a history of blood or
             acupuncture;

          7. (consultation) long-term overconsumption of tea and coffee (more than 8 cups a day, 1
             cup =250mL) A person who drinks coffee or caffeine; Or 48 hours before the study's
             first dose Foods or drinks with caffeine (such as coffee, strong tea, chocolate, etc.)
             affect the absorption of drugs, A special diet of distribution, metabolism, and
             excretion;

          8. (consultation) previous binge drinking (i.e., drinking more than 28 units per week for
             men and more than 28 units per week for women Drink more than 21 units of alcohol (1
             unit contains 14 grams of alcohol, such as 360 mL of beer or 45 mL spirits of 40%
             alcohol or 150 mL wine); Or within 6 months prior to the trial Regular drinkers (more
             than 14 units per week); Or 24 before the first dose of the study Who has taken any
             alcoholic product within an hour;

          9. (consultation) study blood donation or massive bleeding (greater than 450 mL) within 3
             months before initial administration. Or who plans to donate blood or blood components
             during or within 3 months after the study;

         10. (consultation) acute illness during the screening phase before study or before study
             medication;

         11. (consultation) study of patients with liver replacement containing drugs that induce
             or inhibit liver replacement within 24 hours before initial administration Foods or
             drinks containing enzymes (e.g., grapefruit, mango, pitaya, grape juice, orange juice,
             etc.) are abundant Rich in flavonoids or citrus glycosides);

         12. Surgery was performed within three months prior to the screening period or was planned
             for the duration of the study Surgery;

         13. (consultation) previous history of drug abuse; A history of drug abuse;

         14. (consultation) smoking more than 5 cigarettes per day during the 14 days before
             screening, or during the trial Using any tobacco products;

         15. Screening of persons who have smoked or used any tobacco products up to admission;

         16. Positive results of nicotine test;

         17. Alcohol breath test with test results greater than 0.0mg/100ml;

         18. Positive urine drug screening;

         19. Pregnant women or those who plan to become pregnant within 6 months after the end of
             the trial;

         20. The investigator considers that there is anything that may affect the subject's
             informed consent or adherence to the protocol Or participating in the test may affect
             the results of the test or the safety of the personnel under test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ethics committee of drug clinical trials of huazhong university of science and technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

